Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials

This publication has 28 references indexed in Scilit:

• Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial
  The Lancet, 2007
• Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: A case–control study in Nepalese children 5 years after immunization
  Vaccine, 2007
• A live, attenuated recombinant West Nile virus vaccine
  Proceedings of the National Academy of Sciences, 2006
• Cutaneous Delivery of a Live, Attenuated Chimeric Flavivirus Vaccines against Japanese Encephalitis (ChimeriVaxTM-JE) in Non-Human Primates
  Human Vaccines, 2005
• Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax™-JE experimental vaccine
  Vaccine, 2004
• New initiatives for the control of Japanese encephalitis by vaccination:
  Vaccine, 2000
• Immunogenicity, Genetic Stability, and Protective Efficacy of a Recombinant, Chimeric Yellow Fever-Japanese Encephalitis Virus (ChimeriVax-JE) as a Live, Attenuated Vaccine Candidate against Japanese Encephalitis
  Virology, 1999
• Recombinant, chimaeric live, attenuated vaccine (ChimeriVax™) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates
  Vaccine, 1999
• Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study
  The Lancet, 1996
• Protection against Japanese Encephalitis by Inactivated Vaccines
  New England Journal of Medicine, 1988